Bozeman, Mont. and Vancuver, BC — Microbion Corporation announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,464,749 to Microbion with claims to the use of Microbion’s proprietary pravibismane inhaled composition for treatment of pulmonary infections. The patent, entitled “Bismuth-thiol compositions and methods of use,” extends inhaled pravibismane patent protection through mid-2039. The granted claims cover the administration and use of inhaled pravibismane compositions in pulmonary infections. This patent further expands Microbion’s patent portfolio, comprising granted claims to its pravibismane composition and methods of treating infections of the respiratory tract.
“We are pleased that this new patent supporting our inhaled pravibismane program has been granted by the USPTO,” said Karim Lalji, CEO of Microbion Pharma Corp. “This patent is a culmination of many years of work and strengthens our patent position to develop inhaled pravibismane as a potential viable treatment option that addresses several unmet needs for patients living with debilitating lung infection. Having successfully completed GLP toxicology studies, we are excited to be advancing our inhaled development program towards first in human studies.”
Inhaled pravibismane has received QIDP, Fast Track and Orphan drug designation from the US FDA for the treatment (management) of pulmonary infections in patients with cystic fibrosis. Microbion has successfully completed non-clinical studies for the inhaled pravibismane program and is preparing for initiation of clinical trials.
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations.
For more information visit: www.microbioncorp.com.